Publication | Closed Access

A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen

Breast OncologyOncologyHealth SciencesCancer ManagementClinical TrialsRecurrent Breast CancerBreast CancerPharmacotherapyCancer TreatmentMedicineRadiation OncologyPrior Chemotherapy RegimenDouble-blind Phase 2